V. REFERENCES 



19. Bryan, G.T. (1978) Occurrence, production, 

 and uses of nitrofuran. Bryan, G.T., Ed : Car- 

 cinogenesis -A Comprehensive Survey, Vol. 4. 

 Nitrofurans: Chemistry, Metabolism. Mutagene- 

 sis, and Carcinogenesis. New York; Raven 

 Press, pp 111. 



20. Burk,R.F.; Lane, J. M. (1983) Modification of 

 chemical to.xicity by selenium deficiency. Fun- 

 dam. Appl. Toxicol. 3:218-221. 



21 Burns, T.W (1979) Endocrinology Sode- 

 man, W.A., Jr.; Sodeman, T M., Eds.; Pathologic 

 Physiology. Philadelphia: W.B. Saunders Co. 



22. Buzard, J A.; Conklin, J.D., O'Keefe, E.; 

 Paul, M.V. (1961) Studies on the absorption, dis- 

 tribution and elimination of nitrofurantoin in 

 the rat. J Pharmacol. Exp. Ther 131:38-43. 



23. Callen, DP (1981) Comparison of the gene- 

 tic activity of AP'-2 and nitrofurantoin in log and 

 stationary phase cells of Saccharomyces cerevi- 

 siae. Environ. Mutagen. 3:651-658 



24. Chennekatu, PP. Eiurek, J I).; van Zwieten, 

 M.J. (1986) Spontaneous nephropathies in rats. 

 Toxicol. Pathol. 14:91-100. 



25. Clive, D ; Johnson, K O.; Spector, J F S.; 

 Batson, A.G.; Brown, M.M.M. (1979) Validation 

 and characterization of the L5178Y/TK+'- 

 mouse lymphoma mutagen assay system. Mu- 

 tat. Res. 59:61-108. 



26. Cohen, S.M. (1978) Toxicity and carcinogen- 

 icity of nitrofurans. Bryan, G.T, Ed.: Carcino- 

 genesis-A Comprehensive Survey, Vol. 4. Ni- 

 trofurans: Chemistry, Metabolism, Mutagenesis, 

 and Carcinogenesis. New York: Raven Press, 

 pp. 171-231. 



27. Cohen, S.M.; Erturk, E.; Von Esch, A.M.; 

 Crovetti, A.J.; Bryan, G.T (1973) Carcinogenic- 

 ity of 5-nitrofurans, 5-nitroimidazoles, 4-nitro- 

 benzenes, and related compounds. J. Natl. 

 Cancer Inst. 51:403-417. 



28. Conklin, J.D. (1972a) Biopharmaceutics of 

 nitrofurantoin. Pharmacology 8:178-181. 



29. Conklin, J.D. (1972b) Biopharmaceutics of 

 nitrofurantoin. Brodie, B.B.; Heller, W.M., Eds.: 

 Bioavailability of Drugs. Basel-New York: S. 

 Karger, p 178. 



30. Conklin, J.D.; Hailey, F.J. (1969) Urinary 

 drug excretion in man during oral dosage of dif- 

 ferent nitrofurantoin formulations. Clin. Phar- 

 macol. Ther. 10:534-539. 



31. Conklin, J D.: Wagner, D.L. (1971) Excretion 

 of nitrofurantoin in dog hepatic bile Br J 

 Pharmacol. 43:140 150. 



32 Conklin, J.D ; Sobers, R J.; Wagner, D.L 

 (1973) Further studies on nitrofurantoin excre- 

 tion in dog hepatic bile Br J Pharmacol. 



48:273-277. 



33 Cox, DR. (1972) Regression models and life 

 tables. J. R. Stat. Soc. B34:187 220 



34. D'Arcy, P.F (1985) Drug interactions and re 

 actions update: Nitrofurantoin. Drug Intell. 

 Clin. Pharm. 19:540-547. 



35. De Flora, S. (1979) Metabolic activation and 

 deactivation of mutagens and carcinogens. Ital. 

 J. Biochem. 28:81-103. 



36. Delaney, R.A.; Miller, DA.; Gerbino, P.P. 

 ( 1977) Adverse effects resulting from nitrofuran- 

 toin administration Am. J Pharm. 149:26-29. 



37. Dershwitz, M.; Novak, R.F. (1982) Studies on 

 the mechanism of nitrofurantoin mediated red 

 cell toxicity. J. Pharmacol. Exp. Ther. 222:430- 

 434. 



38. Dinse, G.E., Haseman, J.K. (1986) Logistic 

 regression analysis of incidental-tumor data 

 from animal carcinogenicity experiments. Fun- 

 dam. Appl. Toxicol. 6:44-52 



39. Dinse, G.E.; Lagakos, S. W. (1983) Regression 

 analysis of tumour prevalence data. J. R. Stat. 

 Soc. C2:236-248. 



40. Dodd, M.C.; Stillman, W.B. (1944) The in 

 vitro bacteriostatic action of some simple furan 

 derivatives. J. Pharmacol. Exp. Ther. 82:11-18. 



69 



Nitrofurantoin, NTP TR 341 



